|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:adverseEvent
|
anaphylaxis (rare)
febrile seizures (rare)
thrombocytopenia (rare)
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:J07BD52
|
|
gptkbp:boosterRecommended
|
no
|
|
gptkbp:broadcastOn
|
two-dose series
|
|
gptkbp:category
|
combination vaccine
|
|
gptkbp:contains
|
gptkb:human_albumin_(trace_amounts)
sucrose
gelatin
sorbitol
live attenuated viruses
neomycin (trace amounts)
phosphate buffer
|
|
gptkbp:contraindication
|
pregnancy
severe immunodeficiency
|
|
gptkbp:developedBy
|
gptkb:Maurice_Hilleman
|
|
gptkbp:effect
|
over 95% after two doses
|
|
gptkbp:firstDoseAge
|
12-15 months
|
|
gptkbp:herdImmunityThreshold
|
~95%
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MMR vaccine
|
|
gptkbp:immunityDuration
|
long-term
|
|
gptkbp:introducedIn
|
1971
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
gptkb:Serum_Institute_of_India
GlaxoSmithKline
|
|
gptkbp:notLinkedTo
|
autism
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:preventsComplication
|
gptkb:pneumonia
gptkb:congenital_rubella_syndrome
deafness
encephalitis
orchitis
|
|
gptkbp:protectedBy
|
gptkb:measles
gptkb:mumps
gptkb:rubella
|
|
gptkbp:recommendation
|
gptkb:WHO
gptkb:CDC
children
|
|
gptkbp:recommendedDose
|
2 doses
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:secondDoseAge
|
4-6 years
|
|
gptkbp:sideEffect
|
fever
swelling at injection site
mild rash
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:usedIn
|
over 100 countries
routine childhood immunization schedule
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Mumps
gptkb:Rubella
gptkb:Measles
|
|
gptkbp:bfsLayer
|
5
|